GenVec

From Wikipedia, the free encyclopedia

GenVec, Inc.
Type Public (NASDAQ-GM: [1])
Founded
Headquarters Gaithersburg, Maryland, United States Flag of the United States
Key people Paul H. Fischer, President & CEO
Industry Pharmaceuticals
Products TNFeradeTM Phase III
Net income ▼$4.4 million USD (2007)
Website http://genvec.com/


GenVec, Inc. is a biopharmaceutical company developing pharmaceuticals and vaccines based on novel biotechnology such as targeted delivery systems. The company has a number of drugs currently in various phases of clinical trials. Its lead product candidate is TNFerade(TM), being developed for the treatment of solid tumors. The company has been contracted by the United State's Department of Homeland Security to develop a vaccine for Foot-and-mouth disease.[1]

[edit] References

  1. ^ Sinha, Vandana. "GenVec reports narrowed losses", Washington Business Journal, Advance Publications, 2008-03-14. Retrieved on 2008-04-04. (English) 


NASDAQ: GNVC


  This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.